From 21a5e12017ee44a8718dc5d8be4946560e27d9d4 Mon Sep 17 00:00:00 2001
From: Giorgio Sironi <g.sironi@elifesciences.org>
Date: Wed, 8 Jan 2025 10:57:12 +0000
Subject: [PATCH] Add `elifeAssessment` and `version` to all reviewed-preprint
 examples

https://github.com/elifesciences/issues/issues/9034
---
 data/reviewed-preprints/29561.json | 20 +++++++++++++++++++-
 1 file changed, 19 insertions(+), 1 deletion(-)

diff --git a/data/reviewed-preprints/29561.json b/data/reviewed-preprints/29561.json
index e1ebf97d..9f0d9052 100644
--- a/data/reviewed-preprints/29561.json
+++ b/data/reviewed-preprints/29561.json
@@ -26,5 +26,23 @@
   ],
   "curationLabels": [
     "Ground-breaking"
-  ]
+  ],
+  "elifeAssessment": {
+    "title": "eLife assessment",
+    "id": "sa0",
+    "doi": "10.7554/eLife.09562.sa00",
+    "content": [
+      {
+        "type": "paragraph",
+        "text": "Collagen is a major component of extracellular matrix. The authors have identified a high-affinity inhibitory collagen receptor LAIR-1 and a soluble decoy receptor LAIR-2 (with even higher binding affinity to collagen), which can be therapeutically targeted to block tumor progression. Dr Meyaard and colleagues have also generated a dimeric LAIR-2 human IgG1 Fc fusion protein NC410 for therapeutic use. With humanized mouse models engrafted with functional human immune systems (PBMC), they have explored the anti-cancer efficacy of NC410 and revealed its impact on modulating immune responses. Furthermore, they extended this study to identify biomarkers of predictive value for NC410-based anti-cancer therapy."
+      }
+    ],
+    "significance": [
+      "important"
+    ],
+    "strength": [
+      "solid"
+    ]
+  },
+  "version": 1
 }